Media releases Keyword Search Clear 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 18 January 2021 Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy more Published on: 12 January 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab more Published on: 12 January 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer more Published on: 11 January 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer more Published on: 11 January 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years more Published on: 5 January 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer more
Published on: 18 January 2021 Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy more
Published on: 12 January 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab more
Published on: 12 January 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer more
Published on: 11 January 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer more
Published on: 11 January 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years more
Published on: 5 January 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer more